Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest.
Latest Ratings for KZR
DateFirmActionFromTo Dec 2021Wells FargoInitiates Coverage OnOverweight Nov 2021HC Wainwright & Co.MaintainsBuy Jul 2021JonesTradingInitiates Coverage OnBuy